BioMe Inc.

Startup

BioMe, Inc. – Company Description

BioMe, Inc. is a pre-clinical stage biotechnology company dedicated to transforming human healthcare through microbiome-based therapeutics. Leveraging its proprietary SURE™ platform, BioMe establishes clear disease–microbiome connections and accelerates the discovery and development of live biotherapeutic products (LBPs) with well-defined mechanisms of action.

The company’s pipeline targets multiple high-impact indications, including rare metabolic disorders, cardiovascular and renal diseases, antimicrobial resistance, inflammatory bowel diseases, and respiratory immune health. Notably, BM109, a single-strain LBP, is designed to degrade TMA/TMAO and has received FDA Orphan Drug Designation for Trimethylaminuria (TMAU), with expansion potential into cardiovascular and chronic kidney diseases. BM111, a four-strain consortium, is advancing in partnership with Celltrion, Inc. to address multidrug-resistant pathogens such as VRE and CPE. Additional programs, including butyrate-producing BM107 and respiratory-focused BM101, further expand BioMe’s therapeutic reach.

BioMe’s development strategy emphasizes rigorous translational science, efficient Chemistry-Manufacturing-Control (CMC) processes, and global regulatory compliance. Through partnerships with leading pharmaceutical companies, academic institutions, and investors, BioMe is positioned to pioneer a new generation of safe, effective, and patient-centered microbiome therapies.

website